Latest News & Events
Dr. Dennis Slamon presentation talk Tues 28th February 2012 at 7pm
Dr. Dennis Slamon will be giving a talk next Tuesday 28th February 2012 @ 7-8pm in Herbert Park Hotel, Ballsbridge.
If you are interested in attending please reply to .(JavaScript must be enabled to view this email address)
Irish Research Nurses Network (IRNN) 4th Annual Conference 14th October
Registration is now open for the 4th Annual Conference of the Irish Research Nurses Network.
The conference will include a keynote address by Prof Allan Gaw, from the new Clinical Research Facility in Queens University, Belfast, and will feature an expert panel on the topic of informed consent, as well as presentations by research nurses doing their own research, and updates on IRNN activity.
To view details and make a booking please go to the new-look IRNN website irnn.ie
MTCI Symposium
Targets Tissues and Trials
Thursday 13th October 2011
6pm – 8.30pm
Herbert Park Hotel Ballsbridge
For more details on guest speakers see Read More section, and how to reserve your place please view flyer 13th_October_2011_Targerts_Tissues_Trials_(2).pdf
Ireland leads the way in exciting new Lung Cancer Trial
Ireland leads the way in the crizotinib trial with referral from ICORG hospitals all over the country. This has resulted in St. James’s Hospital being the leading European site. All the more exciting when you look at the early data for this drug. In the early phase studies more than 60 percent of lung cancer patients who received crizotinib were alive after two years, according to data released in June 2011.
GSK BRAF Melanoma study in Ireland
Last year ICORG was involved in a strong push to bring the GSK BRAF Melanoma study to this country. It was a highly competitive situation because the early data for BRAF inhibitors hinted strongly that they would be active in melanoma. Only about 20-25% of countries applying to participate worldwide could actually take part.
Nilotinib Leukemia Trial ICORG number 08-02 Completes Accrual
The ICORG 08-02 Nilotinib study has reached its target accrual of 60 patients in May 2011. The last 8 patients were accrued within 8 weeks, just making the mid-May deadline. As a result of this great study teamwork and effort we are able to report on the primary objective for all 60 patients. Upon study completion an abstract has been recently submitted to a top U.S. meeting (American Society of Hematology (ASH)) and we are hopeful that it will be accepted as an oral presentation at the next ASH meeting in December 2011.
